Deep Genomics
PE / VC · Toronto · Canada
Stages
Investment region
Industries
Profile
Deep Genomics is an AI-driven genetic medicines platform company based in Toronto, Ontario, Canada, founded in 2014 by Brendan Frey and Hui Yuan Xiong. The company employs around 100 people and focuses on solving complex molecular design and target biology problems using its Biological Foundation Model (BioFM) Platform. This platform integrates AI model development, lab-in-the-loop workflows, and fit-for-purpose training datasets to accelerate drug discovery. Deep Genomics specializes in drug discovery, particularly in RNA biology, using AI to identify novel targets and therapeutic candidates for genetic conditions. The company operates at the intersection of biotechnology and artificial intelligence, focusing on sectors such as drug discovery, biotechnology, and life sciences. It has raised $238 million in funding from investors like Khosla Ventures, True Ventures, and SoftBank Vision Fund. Notable investments include collaborations with companies like Geneoscopy, CureVac, and Stoke Therapeutics, which are involved in genetic therapy and RNA-based treatments. These partnerships highlight Deep Genomics' commitment to advancing the field of genetic medicine through innovative AI-driven solutions.
Contatos (2)
| Name | Title | Telefone | ||
|---|---|---|---|---|
| Chief Innovation Officer and Founder | — | — | — | |
| Chief Executive Officer | — | — | — |
Name, email and phone are partially hidden. Subscribe to see them in full.